936563-96-1 Ibrutinib (PCI-32765) AKSci X7513
 
 
Loading Please Wait...
  X7513    
Ibrutinib (PCI-32765)
, 98% (HPLC)
 
(R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one




IDENTITY
CAS Number:936563-96-1
MDL Number:MFCD20261150
MF:C25H24N6O2
MW:440.5
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Spectra:HPLC, LCMS, HPLC
Physical Form:White to off-white powder
Density:1.3
Refractive Index:1.69
Long-Term Storage:Store long-term at -20°C
UN #:Not hazmat

BIOLOGICAL INFO
Solubility:DMSO
Application(s):Btk
Form:Free base
Research Area:Leukemia

REVIEW

 Ibrutinib is an experimental anticancer drug recently approved for mantle cell lymphoma. It is a selective and covalent inhibitor of the enzyme Bruton''s tyrosine kinase (BTK). Ibrutinib is currently under development for other B-cell malignancies including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. It was originally synthesized as one of a series of small molecules that inactivate BTK through covalent binding to cysteine-481 near the ATP binding domain of BTK, by means of a Michael acceptor for binding to the target cysteine.

REFERENCES
[1]Honigberg, Lee; Verner, Erik; Pan, Zhengying Preparation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as bruton''s tyrosine kinase inhibitors U.S. Pat. Appl. Publ. (2008), US 20080076921 A1 20080327.
[2] Honigberg, Lee; Verner, Erik; Pan, Zhengying Preparation of substituted pyrazolopyrimidinamines as inhibitors of Bruton''s tyrosine kinase U.S. Pat. Appl. Publ. (2008), US 20080108636 A1 20080508.
[3] Honigberg, Lee; Verner, Erik; Buggy, Joseph J.; Loury, David; Chen, Wei Preparation of substituted pyrazolopyrimidinamines as therapeutic inhibitors of Bruton''s tyrosine kinase and other kinases PCT Int. Appl. (2008), WO 2008121742 A2 20081009.
[4] Pan, Z; Scheerens, H; Li, SJ; Schultz, BE; Sprengeler, PA; Burrill, LC; Mendonca, RV; Sweeney, MD; Scott, KC; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.Discovery of selective irreversible inhibitors for Bruton''s tyrosine kinase. ChemMedChem 2007, 2 (1): 58-61.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of December 11, 2018


Download SDS

CATEGORIES

 APIs and Bioactives > Chemotherapeutics


PubChem